Vor Bio says telitacicept Phase 3 analysis shows 42% minimal symptom expression in gMG through 48 weeks
VOR•Vor Bio said a post hoc analysis of a China Phase 3 trial found 42% of patients with generalized myasthenia gravis had minimal symptom expression through 48 weeks.
1. Trial analysis
Vor Bio released a post hoc analysis of its China Phase 3 trial of telitacicept in generalized myasthenia gravis. The results were presented in an oral session at the MGFA Scientific Session during the 2026 AANEM Annual Meeting. The company said symptom relief was sustained through 48 weeks and safety remained consistent with earlier reports, with no new issues flagged.
